Together we advance new discoveries to new therapies

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single cell genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight.

Our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence.

Breaking down silos to build solutions

LEADERSHIP TEAM

BOARD OF DIRECTORS

Founders

Open minds open doors

We are tackling autoimmune diseases and cancer by elucidating cell stages and types, discovering their interactions and uncovering how and why certain cells become abnormal. To accomplish this, we are deeply engaging with experts across many disciplines to collaborate, co-create and co-invent. We believe strong engagement, scientific depth and knowledge sharing are critical elements of progress.

ThinkLab is a unique model designed to integrate domain expertise, innovate across disciplines and keep Celsius at the forefront of single cell genomics and disease biology.

The ThinkLab consists of four distinct groups:

ThinkLab members are scientific leaders in their field with deep domain expertise in each of the areas above. Working closely with their Celsius’ counterparts, the ThinkLab teams provides hands-on support in driving our target-identification and drug discovery efforts.

THINKLAB MEMBERS:

Single Cell Genomics

Britt Adamson, Ph.D., Assistant Professor at Princeton University
Paul Blainey, Ph.D., Core Member at Broad Institute and Tenured Associate Professor at MIT
Fei Chen, Ph.D., Schmidt Fellow at Broad Institute
Garry Nolan, Ph.D., Professor at Stanford University

Autoimmune

Michael Croft, Ph.D., Professor and Division Head of Immune Regulation at LaJolla Institute for Immunology
Francisco Quintana, Ph.D., Associate Scientist at Brigham and Women’s Hospital and Professor at Harvard Medical School
Greg Sonnenberg, Ph.D., Associate Professor at Weill Cornell Medicine

Immuno-Oncology

Scott Antonia, M.D., Ph.D., Medical Oncologist at Duke Cancer Center
Philip Greenberg, M.D., Head of Immunology at Fred Hutch
Susan Kaech, Ph.D., Professor at Salk Institute for Biological Sciences
David Kaufman, M.D., Chief Medical Officer at Bill and Melinda Gates Medical Research Institute
Miriam Merad, M.D., Ph.D., Professor and Director of Precision Immunology at Mount Sinai School of Medicine

Computational Biology

Barbara Engelhardt, Ph.D., Associate Professor at Princeton University
Peter Kharchenko, Ph.D., Associate Professor at Harvard Medical School
Nir Yosef, Ph.D., Assistant Professor at UC Berkeley

Partnerships

Why partner with Celsius?

We are the leader in the application of single cell genomics to drug discovery and development – a new approach that we believe will revolutionize the pharmaceutical and biotech industry. Our industrialized single cell RNA sequencing and machine learning platform allows for the collection and processing of patient samples on a global scale, the generation of robust and reliable single cell genomic data, and the rapid discovery of novel target and biomarker insights that is positioned to deliver a new generation of precision medicines for complex diseases.

With a focus on single cell genomics, we provide unmatched industry expertise and know-how to our partners. We share our partners’ passion in bringing transformative medicines to patients who are underserved by existing therapies and traditional approaches, and we seek opportunities to leverage our combined strengths to advance the next generation of precision therapeutics.

 

Current partners

Partnerships are at the critical to achieving our vision, and we are fortunate to have strong relationships with leading pharmaceutical companies and academic institutions.

New partnership opportunities

Celsius believes in the power of collaboration – whether it be generation of high-quality single cell data from partner’s samples to broad drug discovery partnerships based on proprietary Celsius insights, we are interested in exploring new opportunities that are consistent with our vision and mission. If interested in partnering with Celsius, please contact us.

Investors

Celsius Therapeutics is a community of scientists, technologists, clinicians and drug hunters leveraging single cell genomic analysis to develop life-changing medicines. Our common goal is to markedly improve human health by integrating data, experience and insight.

Our environment is rigorous, fast-paced and collaborative, bringing together passionate individuals who are making an impact. We inspire creativity and discovery by embracing an open culture that fosters innovation, teamwork and excellence.

Our Investors Include: